Powered by: Motilal Oswal
22/10/2021 3:52:00 PM | Source: Angel One Ltd
Quote on Biocon Q2FY22 number below expectation, stock down 6% By Mr. Yash Gupta, Angel One Ltd
News By Tags | #6943 #271 #607 #6174
Quote on Biocon Q2FY22 number below expectation, stock down 6% By Mr. Yash Gupta, Angel One Ltd

Below is quote on Biocon Q2FY22 number below expectation, stock down 6% by Mr. Yash Gupta, Equity Research Analyst, Angel One Ltd   

Biocon Limited reported revenue from operation at 1840 crores up by 5%, YoY 1750 crores in Q2FY21, Biosimilars has done well for the company up by 10% at ₹743 crores while generics down by 12% at ₹530 crores. The company reported an EBITDA of ₹551 crores up by 35% YoY on the back of better profit margins and product mix. The company reported a net profit of ₹138 crores down by 18% as compared to ₹169 crores in Q2FY21 as the company reported an exceptional loss of ₹50 Crores.

Numbers are below the market expectation biosimilars and research services have done well for the company but generic was down more than 12%.

 

Above views are of the author and not of the website kindly read disclaimer

Disclaimer: The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references. To Read Complete Disclaimer Click Here